| The Govt of the USA, as represented by the Secretary, Dept of Health and Human Services Patent applications |
| Patent application number | Title | Published |
|---|
| 20090160439 | Susceptibility-Matched Multi-Well Sample Holders for High-Throughput Screening by Magnetic Analysis - A method of performing high throughput magnetic sensing of one or more samples. The method comprises selecting a first sample having a first bulk magnetic susceptibility, selecting an assay plate having a second bulk magnetic susceptibility matched to the first bulk magnetic susceptibility, the assay plate including multiple wells, introducing the first sample into a plurality of the wells, and performing magnetic sensing on the plurality of wells containing the first sample. Assay plates, caps, kits, and other devices and methods relating to high throughput magnetic sensing are also disclosed. | 06-25-2009 |
| 20080279886 | Safer Attenuated Virus Vaccines With Missing Or Diminished Latency Of Infection - Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the varicella zoster virus. Deletion of a significant portion from both copies of the varicella zoster gene ORF63 was shown to inhibit establishment of a latent infection from a live vaccine form of the virus. Insertion of an additional ORF62 gene which is partially truncated with the ORF63 deletion inhibited establishment of latency and allowed normal growth of the virus. Other desirable viral antigen encoding sequence(s) and/or cytokine genes advantageously may replace deleted genetic material to enhance a desired immunological response. Aspects of the discovery pertain to live vaccines of other viruses, and can provide a variety of vaccines having greater safety. | 11-13-2008 |
| 20080199443 | Bone Morphogenetic Variants, Compositions and Methods of Treatment - Human cartilage-derived morphogenetic protein variant polypeptides and isolated nucleic acids are provided. Also provided are vectors, host cells, and recombinant methods for producing human cartilage-derived morphogenetic protein variants polypeptides. Therapeutic methods useful for treating musculoskeletal disorders and joint repair with such variants are also provided. | 08-21-2008 |
